Drug and Gene Delivery Devices Market (By Delivery Type: Oral, Ocular, Inhalation, Nasal, Injectable, Transdermal, and Topical; By Method: In Situ and Ex Vivo; By Vector: Viral and Non-Viral) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032

The drug and gene delivery devices market size was estimated at USD 460.9 billion in 2022 and is expected to surpass around USD 932.4 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 7.3% during the forecast period 2023 to 2032.

Drug And Gene Delivery Devices Market Size, 2023 to 2032 (USD Billion )

Key Takeaways:

  • Based on method, the in situ segment accounted largest revenue share in 2022 and is projected to remain its dominance during the forecast period.
  • Based on vector, the viral vector segment accounted largest revenue share in 2022
  • North America dominated the global drug and gene delivery devices market in 2022, in terms of revenue and is estimated to sustain its dominance during the forecast period.

Drug And Gene Delivery Devices Market Report Scope

Report Attribute Details
Market Size in 2023 USD 494.55 Billion
Market Size by 2032 USD 932.4 Billion
Growth Rate From 2023 to 2032 CAGR of 7.3%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Delivery Type, Method, Vector, Region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, Becton, Dickinson and Company, Uniqure NV

 

Growing efforts towards formulating dosage forms that would help in maximizing the bioavailability of the drug at the target site while increasing patient convenience are driving the global market growth. The introduction of novel drug delivery systems such as subdermal implants that are available in different forms such as rings and patches are expected to aid in the industry growth.

The evolution of the drug delivery systems is directly attributed to changing preferences by patients as well as healthcare professionals. A few of the many advancements include

  • Introduction of Biopharmaceutical classification systems (BCS) class II drug in oral dosage forms
  • Introduction of auto-injectors
  • Availability of advanced implants in customized shapes and sizes
  • Introduction of advanced pulmonary devices such as Smartcard and Adaptive Aerosol Delivery

Drug And Gene Delivery Devices Market Trends

The global market for drug and gene delivery devices has expanded with the increased prevalence of numerous chronic diseases, such as cancer, diabetes, cardiovascular diseases, and other technological developments in drug delivery. Additionally, the demand for drug and gene delivery devices has grown with the patients' and physicians' changing preferences, driving the market's expansion.

The market for drug and gene delivery devices is anticipated to rise owing to the increasing need for injectable medications. The global market for drug and gene delivery devices has expanded with the increased prevalence of numerous chronic diseases like cancer, diabetes, cardiovascular diseases, and other technological developments in drug delivery. Additionally, the major players in the field of genomics are increasing their efforts in research and development. The demand for drug and gene delivery devices has grown with the patients' and physicians' changing preferences, driving the market's expansion.

The market for drug and gene delivery devices is anticipated to rise owing to the increasing need for injectable medications. Players in the injectable medicine market are getting regulatory approval for various treatments used in syringes to increase their market share over the forecast period.

The market for drug delivery devices is anticipated to hinder due to regulatory approvals uncertainties. Investments in new product innovations are pushed to the limit due to the possibility of revenue loss from delays in product releases and increased costs paid due to strict regulatory processes, which is impacting the expansion of the drug and gene delivery devices market.

Technological developments in injectable medical equipment have accelerated patient acceptance of self-injectable devices. Since the diabetic patient has to inject insulin regularly, the growing diabetic population is driving the expansion of this market. The rise in popularity of self-injectors, pen-injectors, needle-free injectors, and auto-injectors has made it possible for patients to administer medications at home without needing medical help. The drug and gene delivery device market is anticipated to be significantly impacted by all of these factors, which is expected to increase demand for injectable products over the forecast period.

Delivery Type Insights

Based on delivery type, the oral segment dominated the global drug and gene delivery devices market in 2022, in terms of revenue and is estimated to sustain its dominance during the forecast period. The oral drug delivery is the most convenient and most popular route of administration all over the globe. It is economical, pain-free, and self-administered type of delivery where no sterile precautions are involved. Moreover, the development of various therapeutics that can identify the affected cell and can treat that cell without harming the normal cells is exponentially boosting the growth of this segment. Therefore, the rapid growth of the biosimilar, targeted therapeutics, and gene therapies had positively impacted the market growth in the past few years.

On the other hand, the injectable is estimated to be the most opportunistic segment during the forecast period. The technological advancements in the injectable devices has propelled the adoption of the self-injectable devices among the patients. The rising number of diabetic population is fostering the growth of this segment as the diabetic patient need to regularly inject insulin. The increasing popularity of the self-injectors, needle-free injectors, pen-injectors, and auto-injectors has allowed the patients to conveniently administer drugs from the convenience of their home, eliminating the medical assistance. All these factors are estimated to have a significant impact on the drug and gene delivery devices market and will foster the demand for the injectable segment in the forthcoming years.

Methods Insights

Based on the method used, gene delivery system is segmented as in situ and ex vivo. Most of the currently approved drugs act by in situ methods. Thus, the in situ segment is currently dominating the industry with the largest share.

High focus on the in situ methods owing to its ease of performance is expected to make it the fastest growing segment in the space. However, the segment growth is expected to impede the low efficiency of transduction procedures.

Vector Insights

Viral vectors currently dominate the gene delivery systems market with 4 approved drugs. More than 80% of the ongoing clinical trials on gene therapies are based on the viral vectors for transfection. Thus, the viral segment is expected to remain dominant throughout the forecast period.

Viral vectors enable complex procedures involved in transfection procedures such as gene gun, magnetofection, ultrasound, and hydrodynamic. In addition, it has increased the success rate of the gene transfer as compared to its counterpart techniques

Regional Insights

North America captured the largest market share in 2022. The presence of a large number of key players and high adoption rate of the advanced methods are the factors driving the industry growth in the region. In addition, high investment in R&D by the U.S. government and industry participants is augmenting the industry growth of the region.

Asia Pacific is expected to show a lucrative growth rate during the forecast period owing to factors such as growing awareness about the novel systems as well as the influx of the international industry players to seek opportunities in the untapped market in the region.

Recent Development

  • In June 2022, Roche announced the launch of its Human papillomavirus (HPV) self-sampling equipment. HPV screening assists in identifying women who are at risk of developing cervical cancer, allowing early diagnosis and treatment of the problem.
  • Key players operating in the gene delivery systems include Uniqure N.V., SiBiono GeneTech Co., Epeius Biotechnologies Corporation, Shanghai Sunway Biotech Co., Ltd, and Human Stem Cells Institute. These companies are also engaged in the R&D of their products to explore further applications in different physiological conditions.

Some of the prominent players in the Drug And Gene Delivery Devices Market include:

  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson and Johnson Private Ltd
  • Novartis AG
  • Bayer AG
  • Becton, Dickinson and Company
  • Uniqure NV

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Drug And Gene Delivery Devices market.

By Delivery Type

  • Oral
  • Ocular
  • Inhalation
  • Nasal
  • Injectable
  • Transdermal
  • Topical

By Method

  • In Situ
  • Ex Vivo

By Vector

  • Viral Vector
  • Non-Viral Vector

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The drug and gene delivery devices market size was estimated at USD 460.9 billion in 2022 and is expected to surpass around USD 932.4 billion by 2032

The global drug and gene delivery devices market is expected to grow at a compound annual growth rate of 7.3% from 2017 to 2025

Some key players operating in the drug and gene delivery devices market include Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, and Becton, Dickinson and Company.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Drug and Gene Delivery Devices Market 

5.1. COVID-19 Landscape: Drug and Gene Delivery Devices Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Drug and Gene Delivery Devices Market, By Delivery

8.1. Drug and Gene Delivery Devices Market, by Delivery Type, 2023-2032

8.1.1. Oral

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Ocular

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Inhalation

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Nasal

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Injectable

8.1.5.1. Market Revenue and Forecast (2020-2032)

8.1.6. Transdermal

8.1.6.1. Market Revenue and Forecast (2020-2032)

8.1.7. Topical

8.1.7.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Drug and Gene Delivery Devices Market, By Method

9.1. Drug and Gene Delivery Devices Market, by Method, 2023-2032

9.1.1. In Situ

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Ex Vivo

9.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Drug and Gene Delivery Devices Market, By Vector 

10.1. Drug and Gene Delivery Devices Market, by Vector, 2023-2032

10.1.1. Viral Vector

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Non-Viral Vector

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Drug and Gene Delivery Devices Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.1.2. Market Revenue and Forecast, by Method (2020-2032)

11.1.3. Market Revenue and Forecast, by Vector (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Method (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Vector (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Method (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Vector (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.2.2. Market Revenue and Forecast, by Method (2020-2032)

11.2.3. Market Revenue and Forecast, by Vector (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Method (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Vector (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Method (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Vector (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Method (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Vector (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Method (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Vector (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.3.2. Market Revenue and Forecast, by Method (2020-2032)

11.3.3. Market Revenue and Forecast, by Vector (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Method (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Vector (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Method (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Vector (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Method (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Vector (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Method (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Vector (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.4.2. Market Revenue and Forecast, by Method (2020-2032)

11.4.3. Market Revenue and Forecast, by Vector (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Method (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Vector (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Method (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Vector (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Method (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Vector (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Method (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Vector (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.5.2. Market Revenue and Forecast, by Method (2020-2032)

11.5.3. Market Revenue and Forecast, by Vector (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Method (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Vector (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Delivery (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Method (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Vector (2020-2032)

Chapter 12. Company Profiles

12.1. Pfizer, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. F. Hoffmann-La Roche Ltd

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Johnson and Johnson Private Ltd

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Novartis AG

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Bayer AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Becton, Dickinson and Company

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Uniqure NV

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers